Skip to main content

Articles

Page 139 of 141

  1. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study was the first trial to assess whether statins might be of clinical benefit in those with recently unstable coronary disease. M...

    Authors: Herbert D Aronow

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:3

    Content type: Commentary

    Published on:

  2. Although diabetes mellitus is predominantly a metabolic disorder, recent data suggest that it is as much a vascular disorder. Cardiovascular complications are the leading cause of death and disability in patie...

    Authors: Prakash C Deedwania

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:2

    Content type: Review

    Published on:

  3. Overweight older adults are often counseled to lose weight, even though there is little evidence of excess mortality in that age group. Overweight and underweight may be more associated with health status than...

    Authors: Paula Diehr, Anne B Newman, Sharon A Jackson, Lewis Kuller and Neil Powe

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:1

    Content type: Research

    Published on:

  4. The treatment of patients with coronary artery disease continues to evolve; all three strategies – medical therapy, surgical revascularization, and percutaneous coronary intervention – have changed. Medical th...

    Authors: David R Holmes Jr

    Citation: Trials 2001 2:263

    Content type: Commentary

    Published on:

  5. This commentary has two purposes: to summarize the rationale, design and initial results of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial; and to provide a hist...

    Authors: Lawrence R Krakoff

    Citation: Trials 2001 2:254

    Content type: Commentary

    Published on:

  6. The identification of angiogenic growth factors, such as vascular endothelial growth factor and fibroblast growth factor, has fueled interest in using such factors to induce therapeutic angiogenesis. The resul...

    Authors: Yin-Shan Ng and Patricia A D'Amore

    Citation: Trials 2001 2:278

    Content type: Review

    Published on:

  7. The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascula...

    Authors: Lutgarde Thijs, Jan A Staessen, Sonia Beleva, Willem H Birkenhäger, Christopher J Bulpitt, Hilde Celis, Astrid E Fletcher, Rumjana Kermova, Gastone Leonetti, Tovio Laks, Stefan Mantov, Choudomir Nachev, Cinzia Sarti, Jaakko Tuomilehto and Robert H Fagard

    Citation: Trials 2001 2:298

    Content type: Research

    Published on:

  8. Inflammatory cytokines may negatively influence contractility and contribute to the remodelling process in the failing myocardium. Traditional cardiovascular drugs appear to have little influence on the overal...

    Authors: Jan Kristian Damås, Lars Gullestad and Pål Aukrust

    Citation: Trials 2001 2:271

    Content type: Review

    Published on:

  9. Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the f...

    Authors: Curt D Furberg and Bertram Pitt

    Citation: Trials 2001 2:205

    Content type: Commentary

    Published on:

Annual Journal Metrics